Vislyfa

How to take it

These directions are for this exact strength and form. Another one is different.

• Vislyfa is administered as a single injection into your eye by your eye doctor under a local anaesthetic.
• The usual dose of an injection is 0.05 mL (which contains 0.5 mg of ranibizumab). The interval between two doses injected into the same eye should be at least four weeks. All injections will be administered by your eye doctor.
• Before the injection, your doctor will wash your eye carefully to prevent infection. Your doctor will also give you a local anaesthetic to reduce or prevent any pain you might have with the injection.
• The treatment is started with one injection of Vislyfa per month. Your doctor will monitor the condition of your eye and, depending on how you respond to the treatment, will decide if and when you need to receive further treatment.
• Detailed instructions for use are given at the end of the leaflet under “How to prepare and administer Vislyfa to adults”.
• Elderly (age 65 years and over)
• Vislyfa can be used for people of 65 years of age and over without dose adjustment.
• Before stopping Vislyfa treatment If you are considering stopping Vislyfa treatment, please go to your next appointment and discuss this with your doctor. Your doctor will advise you and decide how long you should be treated with Vislyfa.
• If you have any further questions on the use of this medicine, ask your doctor.

From the package leaflet in EMA’s product information, p. 62–63.

Warnings and precautions

From the package leaflet in EMA’s product information, p. 62.

Pregnancy and breastfeeding

From the package leaflet in EMA’s product information, p. 62.

Other medicines

From the package leaflet in EMA’s product information, p. 62.

Driving and using machines

• After Vislyfa treatment you may experience some temporary vision blurring. If this happens, do not drive or use machines until this resolves.
• This medicine contains polysorbate 20 This medicine contains 0.005 mg of polysorbate 20 in each dose of 0.05 mL which is equivalent to 0.1 mg/mL. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

From the package leaflet in EMA’s product information, p. 62.

Side effects

• Like all medicines, this medicine can cause side effects, although not everybody gets them.
• The side effects associated with the administration of Vislyfa are either due to the medicine itself or the injection procedure and mostly affect the eye.
• The most serious side effects are described below:
• Common serious side effects (may affect up to 1 in 10 people): Detachment or tear of the layer in the back of the eye (retinal detachment or tear), resulting in flashes of light with floaters progressing to a temporary loss of sight, or a clouding of the lens (cataract).
• Uncommon serious side effects (may affect up to 1 in 100 people): Blindness, infection of the eyeball (endophthalmitis) with inflammation of the inside of the eye.
• The symptoms you might experience are pain or increased discomfort in your eye, worsening eye redness, blurred or decreased vision, an increased number of small particles in your vision or increased sensitivity to light. Please tell your doctor immediately if you develop any of these side effects.
• The most frequently reported side effects are described below:
• Very common side effects (may affect more than 1 in 10 people)
• Visual side effects include: Inflammation of the eye, bleeding in the back of the eye (retinal bleeding), visual disturbances, eye pain, small particles or spots in your vision (floaters), bloodshot eye, eye irritation, a feeling of having something in the eye, increased tear production, inflammation or infection of the eyelid margins, dry eye, redness or itching of the eye and increased eye pressure.
• Non-visual side effects include: Sore throat, nasal congestion, runny nose, headache and joint pain.
• Other side effects which may occur following Vislyfa treatment are described below:
• Common side effects Visual side effects include: Decreased sharpness of vision, swelling of a section of the eye (uvea, cornea), inflammation of the cornea (front part of eye), small marks on the surface of the eye, blurred vision, bleeding at the site of injection, bleeding in the eye, discharge from the eye with itching, redness and swelling (conjunctivitis), light sensitivity, eye discomfort, swelling of the eyelid, eyelid pain.
• Non-visual side effects include: Urinary tract infection, low red blood cells count (with symptoms such as tiredness, breathlessness, dizziness, pale skin), anxiety, cough, nausea, allergic reactions like rash, hives, itching and skin reddening.
• Uncommon side effects Visual side effects include: Inflammation and bleeding in the front part of the eye, sac of pus on the eye, changes of the central part of the eye surface, pain or irritation at the site of injection, abnormal sensation in the eye, irritation of the eyelid.
• Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

From the package leaflet in EMA’s product information, p. 63–64.

How to store it

• Keep this medicine out of the sight and reach of children.
• Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. The expiry date refers to the last day of that month.
• Store in a refrigerator (2 °C – 8 °C). Do not freeze.
• Prior to use, the unopened vial may be kept at room temperature (25 °C) for up to 24 hours.
• Keep the vial in the outer carton in order to protect from light.
• Do not use any pack that is damaged.

From the package leaflet in EMA’s product information, p. 64.

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Details

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

Report wrong or outdated information on this page

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

See every product with Ranibizumab